Abstract
Until superior therapeutic treatments are developed to prevent, treat and cure
cancer, the best means of reducing mortality and morbidity in a disease this
complex is early detection and diagnosis. In the major solid cancer types such
as lung, breast, colon and prostate, long-term survival rates drop
precipitously once metastatis has occurred. The case is clear for development
of biomarkers for early detection and screening tests for diseases such as
breast, colon, ovarian and lung cancer. In addition, diagnostic measurement of
cancer disease progression is essential to successful disease management. For
these reasons, development of new and effective biomarkers for cancer
detection and diagnosis is central to the cancer problem. The use of nucleic
acid biomarker diagnostics have begun to answer these questions. Protein
biomarkers are also useful. The purpose of this TriMark Publications report is
to describe the specific segment of the cancer diagnostics market which
develops new biomarker technology platforms for diagnosing and treating
cancer. Biomarkers are useful in following the course of cancer and evaluating
which therapeutic regimes are most effective for a particular type of cancer,
as well as determining long-term susceptibility to cancer or recurrence. This
study particularly examines those clinical measurement devices, and their
reagents and supplies, which are meant to be used in hospitals, clinics,
commercial laboratories and doctor' s offices to diagnose and monitor cancer.
The examination also provides an in-depth discussion of the application of
biomarkers in developing novel targeted cancer therapeutics, their predication
response and efficacy, as well as their use in diagnosis of cancer.
The main objectives of this analysis are:
- Identifying viable technology drivers for cancer biomarkers and related
companion diagnostics through a comprehensive look at platform technologies
including, probe-based nucleic acid assays, microarrays and sequencing, and
mass spectroscopy.
- Obtaining a complete understanding of the new cancer biomarker diagnostic
tests-i.e., predictive, screening, prognostic, monitoring, pharmacogenomic and
theranostic-from their basic principles to their applications.
- Discovering growing market opportunities by identifying high-growth
applications in different cancer diagnostic areas, focusing on the biggest and
expanding markets in oncology (e.g., biomarkers for breast cancer and
predictive biomarkers).
- Focusing on global industry development through an in-depth analysis of
the major world markets for cancer diagnostics, including growth forecasts.
This analysis emphasizes companies that are actively developing and marketing
new reagents and supplies for performing cancer biomarker diagnostics tests.
It discusses the various market trends and opportunities using new biomarkers,
while providing an in-depth analysis of market share, revenue forecasts, and
market drivers and restraints. The comprehensive focus of the study, backed by
strategic recommendations, enables companies to position their growth
strategies to benefit from the changing market conditions and obtain maximum
return on investment.
This study surveys biotech companies known for marketing, manufacturing or
developing instruments and reagents for the clinical cancer diagnostics
market, both in the U.S. and the world. Leading companies are discussed
in-depth, with sections on the companies' histories, product lines, business
and marketing analyses, and subjective commentary on the companies' market
positions.
This report answers the questions:
- Which companies are utilizing cutting-edge technologies to develop,
validate, and implement cancer biomarkers for clinical use?
- What impediments still exist to incorporating promising research into
clinical practice?
- Which cancer biomarkers show the most promise for approval?
- What are the economic challenges to approval?
- How can regulatory oversight drive approval and adoption of new
technologies?
- Which alliances show the greatest synergy in bringing valid biomarkers to
market?
- Which shared technologies are driving the most encouraging development?
| 
View Cart
